Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab maintenance after R-CHOP vs R-FC in elderly mantle cell lymphoma
2005-005375-15Phase 3Completed
- Sponsor
- Groupe d'Étude des Lymphomes de l'Adulte
- Start
- Jan 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in mantle cell lymphoma (MCL) (4 arms), sponsored by Groupe d'Étude des Lymphomes de l'Adulte. Primary endpoints: Complete response rate after initial chemotherapy, Progression-free survival after initial chemotherapy and 1 more. Started Jan 2006; status: completed.
02
Drugs
rituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2005-005375-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005375-15.